Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| HTCO | High-Trend International Group | $27.62 | $16.37 | 145.51% | 4.5M | $83M | $4.55$61.75 |
| UCAR | U Power | $2.44 | $0.80 | 48.77% | 17.4M | $3.5M | $0.38$49.80 |
| SGMT | Sagimet Biosciences | $8.53 | $2.67 | 45.56% | 39.7M | $191M | $3.03$11.41 |
| MANE | Veradermics | $92.27 | $24.43 | 36.00% | 2.1M | $2.5B | $17.00$101.81 |
| EUDA | Euda Health | $13.09 | $2.47 | 23.26% | 309.8K | $27M | $5.26$86.00 |
| EDSA | Edesa Biotech | $8.92 | $1.66 | 22.86% | 977.7K | $61M | $0.72$9.63 |
| ORKA | Oruka Therapeutics | $83.54 | $14.51 | 21.02% | 4.4M | $3.4B | $8.91$91.00 |
| QUIK | QuickLogic | $15.81 | $2.73 | 20.89% | 1.8M | $232M | $4.80$16.89 |
| RMAX | RE/MAX Holdings | $9.64 | $1.65 | 20.65% | 11.1M | $161M | $5.46$10.32 |
| THRY | Thryv | $3.90 | $0.58 | 17.47% | 41.7K | $147M | $1.91$15.49 |
| ANAB | AnaptysBio | $68.96 | $10.08 | 17.12% | 29K | $1.7B | $11.40$70.07 |
| OGN | Organon & Co. | $13.18 | $1.92 | 17.01% | 89M | $2.9B | $5.69$13.25 |
| DWSN | Dawson Geophysical | $3.76 | $0.52 | 15.90% | 216.1K | $101M | $1.08$5.54 |
| CLIK | Click | $3.16 | $0.41 | 14.91% | 157.2K | $9.0M | $1.32$34.20 |
| ABSI | Absci | $4.52 | $0.58 | 14.72% | 390.8K | $603M | $2.24$5.23 |
| LOCL | Local Bounti | $2.63 | $0.33 | 14.35% | 108.2K | $52M | $0.98$4.00 |
| IMUX | Immunic | $10.02 | $1.22 | 13.85% | 241.6K | $1.1B | $5.06$15.10 |
| ZJK | Zjk Industrial | $2.79 | $0.33 | 13.41% | 18.5K | $157M | $1.45$5.82 |
| UECG | Themes ETF Trust - Leverage Shares 2x Long Uec Daily ETF | $10.21 | $1.20 | 13.33% | 41.2K | - | $6.75$15.46 |
| MNTS | Momentus | $6.41 | $0.75 | 13.25% | 1.6M | $32M | $3.11$43.55 |
| QNTM | Quantum BioPharma Ltd. | $4.08 | $0.47 | 13.02% | 25.8K | $21M | $2.07$38.25 |
| REPL | Replimune Group | $2.74 | $0.32 | 13.02% | 2.7M | $200M | $1.50$13.24 |
| MULL | GraniteShares ETF Trust - GraniteShares 2x Long Mu Daily ETF | $245.95 | $26.51 | 12.08% | 219.2K | - | $8.01$249.20 |
| LFVN | LifeVantage | $5.69 | $0.61 | 12.01% | 191.7K | $65M | $3.90$15.00 |
| TRAK | ReposiTrak | $9.06 | $0.94 | 11.58% | 295.2K | $148M | $6.94$23.72 |
| MUU | Direxion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares | $278.50 | $28.40 | 11.36% | 1.4M | - | $9.00$284.05 |
| ATXG | Addentax Group | $5.32 | $0.53 | 10.96% | 7.5K | $3.7M | $3.32$27.90 |
| YDDL | One And One Green Technologies. | $5.12 | $0.50 | 10.82% | 129.6K | $249M | $3.61$16.23 |
| STI | Solidion Technology | $4.52 | $0.44 | 10.66% | 57.8K | $32M | $2.94$33.99 |
Related Articles
Featured Article
Is This Healthcare Stock's 10% Yield a Steal of a Deal or Too Good to Be True?
David Jagielski, CPA|Nov 21, 2023
High-yielding stocks may be tantalizing, but they often come with risks.
Need an Extra $4,000 in Dividends Each Year? Invest $68,000 in These 3 Stocks.
David Jagielski, CPA|Jul 21, 2023
These stocks can significantly bolster your income.
Want $5,000 in Annual Dividend Income? Invest in These 3 Stocks
David Jagielski, CPA|Jun 29, 2023
These stocks are down more than 5% this year, and now may be a good time to add them to your portfolio.
Could the Owner of the Yellow Pages Be the Next Multibillion-Dollar SaaS Company?
Michael Byrne|Apr 12, 2022
Don't close the book on the Yellow Pages operator just yet.
3 of the Best Value Stocks to Buy Heading Into April
David Jagielski, CPA|Mar 30, 2022
With these shares at modest valuations, you can score some cheap long-term investments.
Should Investors Hold Out Hope for bluebird bio and Merck Spinoff Organon?
Keith Speights and Brian Orelli, PhD|Jul 10, 2021
Neither healthcare stock has performed well so far this year.
Learning From Stock Market Losers
Motley Fool Staff|Jan 14, 2021
Rule Breaker Investing: David's Biggest Losers Volume 6
2 Biotech Stocks That Could Have Tripled Your Money This Year
Cory Renauer|Nov 15, 2020
One has a better chance to keep climbing than the other does.
2 Top Biotech Stocks From the IPO Class of 2018 to Buy Now
Cory Renauer|Nov 4, 2020
Compelling clinical trial results so far make these biotech stocks worth more attention than they've received so far.
Better Buy: AnaptysBio vs. Exelixis
David Haen|Apr 24, 2020
Key clinical trial results this quarter will determine the better buy.
